AUTOGEL Studie - phase III, randomised, double blind, stratified comparative, placebo controlled. Parallel groub, multicenter study to assess the effect of deep subcutaneous injections of lanreotide autogel 120 mg administered every 28 days on tumor progression free survival in patients with non functioning entero-pancreatic endocrine tumour
Laufzeit: 01.01.2007 - 31.12.2015